;PMID: 1988174
;source_file_1007.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..197] = [t:43..197]
;2)section:[e:201..275] = [t:201..275]
;3)section:[e:279..331] = [t:279..331]
;4)sentence:[e:335..561] = [t:335..561]
;5)sentence:[e:562..803] = [t:562..803]
;6)sentence:[e:804..914] = [t:804..914]
;7)sentence:[e:915..1225] = [t:915..1225]
;8)sentence:[e:1226..1383] = [t:1226..1383]
;9)sentence:[e:1384..1704] = [t:1384..1704]
;10)sentence:[e:1705..1846] = [t:1705..1846]
;11)sentence:[e:1847..2003] = [t:1847..2003]
;12)sentence:[e:2004..2159] = [t:2004..2159]
;13)sentence:[e:2160..2350] = [t:2160..2350]
;14)sentence:[e:2351..2559] = [t:2351..2559]
;15)section:[e:2563..2607] = [t:2563..2607]

;section 0 Span:0..37
;Carcinogenesis. 1991 Jan;12(1):133-9.
(SEC
  (FRAG (RB:[0..14] Carcinogenesis) (IN:[14..15] .) (CD:[16..20] 1991)
        (CC:[21..28] Jan;12-LRB-) (CD:[28..29] 1) (-RRB-:[29..30] -RRB-)
        (CD:[30..34] :133) (::[34..35] -) (CD:[35..37] 9.)))

;sentence 1 Span:43..197
;Roles of different cytochrome P450 enzymes in bioactivation of the potent 
;hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver
;microsomes.
;[62..85]:cyp450:"cytochrome P450 enzymes"
;[118..134]:substance:"hepatocarcinogen"
;[135..162]:substance:"3-methoxy-4-aminoazobenzene"
(SENT
  (NP-HLN
    (NP (NNS:[43..48] Roles))
    (PP (IN:[49..51] of)
      (NP (JJ:[52..61] different)
        
        (NML (NN:[62..72] cytochrome) (NN:[73..77] P450))
        (NNS:[78..85] enzymes)))
    (PP (IN:[86..88] in)
      (NP
        (NP (NN:[89..102] bioactivation))
        (PP (IN:[103..105] of)
          (NP
            (NP (DT:[106..109] the) (JJ:[110..116] potent)
                (NN:[118..134] hepatocarcinogen))
            (NP (NN:[135..162] 3-methoxy-4-aminoazobenzene))))
        (PP (IN:[163..165] by)
          (NP
            (NP (NN:[166..169] rat)
              (NML-1 (-NONE-:[169..169] *P*)))
            (CC:[170..173] and)
            (NP (JJ:[174..179] human)
              (NML-1 (NN:[180..185] liver) (NNS:[186..196] microsomes)))))))
    (.:[196..197] .)))

;section 2 Span:201..275
;Yamazaki H, Degawa M, Funae Y, Imaoka S, Inui Y, Guengerich FP, Shimada T.
(SEC
  (FRAG (NNP:[201..209] Yamazaki) (NNP:[210..211] H) (,:[211..212] ,)
        (NNP:[213..219] Degawa) (NNP:[220..222] M,) (NNP:[223..228] Funae)
        (NNP:[229..230] Y) (,:[230..231] ,) (NNP:[232..238] Imaoka)
        (NNP:[239..241] S,) (NNP:[242..246] Inui) (NNP:[247..248] Y)
        (,:[248..249] ,) (NNP:[250..260] Guengerich) (NNP:[261..263] FP)
        (,:[263..264] ,) (NNP:[265..272] Shimada) (NNP:[273..275] T.)))

;section 3 Span:279..331
;Osaka Prefectural Institute of Public Health, Japan.
(SEC
  (FRAG (NNP:[279..284] Osaka) (NNP:[285..296] Prefectural)
        (NNP:[297..306] Institute) (IN:[307..309] of) (NNP:[310..316] Public)
        (NNP:[317..323] Health) (,:[323..324] ,) (NNP:[325..330] Japan)
        (.:[330..331] .)))

;sentence 4 Span:335..561
;The potent hepatocarcinogen 3-methoxy-4-aminoazobenzene (3-MeO-AAB) has been 
;reported to be bioactivated to mutagenic intermediates by rat liver
;microsomal  cytochrome P450 (P450) and to be a selective inducer of rat
;P450IA2.
;[346..362]:substance:"hepatocarcinogen"
;[363..390]:substance:"3-methoxy-4-aminoazobenzene"
;[392..401]:substance:"3-MeO-AAB"
;[454..467]:substance:"intermediates"
;[493..508]:cyp450:"cytochrome P450"
;[510..514]:cyp450:"P450"
;[538..545]:substance:"inducer"
;[553..560]:cyp450:"P450IA2"
(SENT
  (S
    (NP-SBJ-2 (DT:[335..338] The) (JJ:[339..345] potent)
              (NN:[346..362] hepatocarcinogen)
      (NP
        (NP (NN:[363..390] 3-methoxy-4-aminoazobenzene))
        (NP (-LRB-:[391..392] -LRB-) (NN:[392..401] 3-MeO-AAB)
            (-RRB-:[401..402] -RRB-))))
    (VP (VBZ:[403..406] has)
      (VP (VBN:[407..411] been)
        (VP (VBN:[413..421] reported)
          (NP-2 (-NONE-:[421..421] *))
          (S
            (NP-SBJ-1 (-NONE-:[421..421] *))
            (VP
              (VP (TO:[422..424] to)
                (VP (VB:[425..427] be)
                  (VP (VBN:[428..440] bioactivated)
                    (NP-1 (-NONE-:[440..440] *))
                    (PP (TO:[441..443] to)
                      (NP (JJ:[444..453] mutagenic)
                          (NNS:[454..467] intermediates)))
                    (PP (IN:[468..470] by)
                      (NP-LGS (NN:[471..474] rat) (NN:[475..480] liver)
                              (JJ:[481..491] microsomal)
                        (NML
                          (NML (NN:[493..503] cytochrome) (NN:[504..508] P450))
                          (NML (-LRB-:[509..510] -LRB-) (NN:[510..514] P450)
                               (-RRB-:[514..515] -RRB-))))))))
              (CC:[516..519] and)
              (VP (TO:[520..522] to)
                (VP (VB:[523..525] be)
                  (NP-PRD
                    (NP (DT:[526..527] a) (JJ:[528..537] selective)
                        (NN:[538..545] inducer))
                    (PP (IN:[546..548] of)
                      (NP (NN:[549..552] rat) (NN:[553..560] P450IA2)))))))))))
    (.:[560..561] .)))

;sentence 5 Span:562..803
;In this  study we have further investigated the roles of individual rat and
;human P450  enzymes in the bioactivation of this hepatocarcinogen in a
;Salmonella  typhimurium TA1535/pSK1002 system where umu response is
;indicative of DNA  damage.
;[644..657]:cyp450:"P450  enzymes"
;[687..703]:substance:"hepatocarcinogen"
;[791..794]:substance:"DNA"
(SENT
  (S
    (PP (IN:[562..564] In)
      (NP (DT:[565..569] this) (NN:[571..576] study)))
    (NP-SBJ (PRP:[577..579] we))
    (VP (VBP:[580..584] have)
      (ADVP (RBR:[585..592] further))
      (VP (VBN:[593..605] investigated)
        (NP
          (NP (DT:[606..609] the) (NNS:[610..615] roles))
          (PP (IN:[616..618] of)
            (NP
              (NP
                (ADJP-3 (JJ:[619..629] individual))
                (NN:[630..633] rat)
                (NML-2 (-NONE-:[633..633] *P*)))
              (CC:[634..637] and)
              (NP
                (ADJP-3 (-NONE-:[637..637] *P*))
                (JJ:[638..643] human)
                (NML-2 (NN:[644..648] P450) (NNS:[650..657] enzymes))))))
        (PP (IN:[658..660] in)
          (NP
            (NP (DT:[661..664] the) (NN:[665..678] bioactivation))
            (PP (IN:[679..681] of)
              (NP (DT:[682..686] this) (NN:[687..703] hepatocarcinogen)))
            (PP (IN:[704..706] in)
              (NP
                (NP (DT:[707..708] a) (NNP:[709..719] Salmonella)
                    (NNP:[721..732] typhimurium)
                  (NML (NN:[733..739] TA1535) (SYM:[739..740] /)
                       (NN:[740..747] pSK1002))
                  (NN:[748..754] system))
                (SBAR
                  (WHADVP-1 (WRB:[755..760] where))
                  (S
                    (NP-SBJ (NN:[761..764] umu) (NN:[765..773] response))
                    (VP (VBZ:[774..776] is)
                      (ADJP-PRD (JJ:[777..787] indicative)
                        (PP (IN:[788..790] of)
                          (NP (NN:[791..794] DNA) (NN:[796..802] damage))))
                      (ADVP-1 (-NONE-:[802..802] *T*)))))))))))
    (.:[802..803] .)))

;sentence 6 Span:804..914
;3-MeO-AAB was found to be bioactivated by liver microsomal enzymes from  rats
;and humans in this assay system.
;[804..813]:substance:"3-MeO-AAB"
;[863..870]:substance:"enzymes"
(SENT
  (S
    (NP-SBJ-1 (NN:[804..813] 3-MeO-AAB))
    (VP (VBD:[814..817] was)
      (VP (VBN:[818..823] found)
        (S
          (NP-SBJ-1 (-NONE-:[823..823] *))
          (VP (TO:[824..826] to)
            (VP (VB:[827..829] be)
              (VP (VBN:[830..842] bioactivated)
                (NP-1 (-NONE-:[842..842] *))
                (PP (IN:[843..845] by)
                  (NP-LGS
                    (NP (NN:[846..851] liver) (JJ:[852..862] microsomal)
                        (NNS:[863..870] enzymes))
                    (PP (IN:[871..875] from)
                      (NP (NNS:[877..881] rats) (CC:[882..885] and)
                          (NNS:[886..892] humans)))))
                (PP (IN:[893..895] in)
                  (NP (DT:[896..900] this) (NN:[901..906] assay)
                      (NN:[907..913] system)))))))))
    (.:[913..914] .)))

;sentence 7 Span:915..1225
;The liver microsomal activities are  increased by pretreatment of rats with
;various P450 inducers such as  phenobarbital (PB), beta-naphthoflavone (BNF),
;dexamethasone (DEX), acetone,  ethanol, isoniazid (INH), diphenylhydantoin
;and valproic acid, and can be  inhibited considerably by SKF-525A and
;metyrapone.
;[999..1003]:cyp450:"P450"
;[1004..1012]:substance:"inducers"
;[1022..1035]:substance:"phenobarbital"
;[1037..1039]:substance:"PB"
;[1042..1061]:substance:"beta-naphthoflavone"
;[1063..1066]:substance:"BNF"
;[1069..1082]:substance:"dexamethasone"
;[1084..1087]:substance:"DEX"
;[1090..1097]:substance:"acetone"
;[1100..1107]:substance:"ethanol"
;[1109..1118]:substance:"isoniazid"
;[1120..1123]:substance:"INH"
;[1126..1143]:substance:"diphenylhydantoin"
;[1148..1161]:substance:"valproic acid"
;[1201..1209]:substance:"SKF-525A"
;[1214..1224]:substance:"metyrapone"
(SENT
  (S
    (NP-SBJ-1 (DT:[915..918] The) (NN:[919..924] liver)
              (JJ:[925..935] microsomal) (NNS:[936..946] activities))
    (VP
      (VP (VBP:[947..950] are)
        (VP (VBN:[952..961] increased)
          (NP-1 (-NONE-:[961..961] *))
          (PP (IN:[962..964] by)
            (NP-LGS
              (NP (NN:[965..977] pretreatment))
              (PP (IN:[978..980] of)
                (NP (NNS:[981..985] rats)))
              (PP (IN:[986..990] with)
                (NP
                  (NP (JJ:[991..998] various) (NN:[999..1003] P450)
                      (NNS:[1004..1012] inducers))
                  (PP (JJ:[1013..1017] such) (IN:[1018..1020] as)
                    (NP
                      (NP
                        (NP (NN:[1022..1035] phenobarbital))
                        (NP (-LRB-:[1036..1037] -LRB-) (NN:[1037..1039] PB)
                            (-RRB-:[1039..1040] -RRB-)))
                      (,:[1040..1041] ,)
                      (NP
                        (NP (NN:[1042..1061] beta-naphthoflavone))
                        (NP (-LRB-:[1062..1063] -LRB-) (NN:[1063..1066] BNF)
                            (-RRB-:[1066..1067] -RRB-)))
                      (,:[1067..1068] ,)
                      (NP
                        (NP (NN:[1069..1082] dexamethasone))
                        (NP (-LRB-:[1083..1084] -LRB-) (NN:[1084..1087] DEX)
                            (-RRB-:[1087..1088] -RRB-)))
                      (,:[1088..1089] ,)
                      (NP (NN:[1090..1097] acetone))
                      (,:[1097..1098] ,)
                      (NP (NN:[1100..1107] ethanol))
                      (,:[1107..1108] ,)
                      (NP
                        (NP (NN:[1109..1118] isoniazid))
                        (NP (-LRB-:[1119..1120] -LRB-) (NN:[1120..1123] INH)
                            (-RRB-:[1123..1124] -RRB-)))
                      (,:[1124..1125] ,)
                      (NP (NN:[1126..1143] diphenylhydantoin))
                      (CC:[1144..1147] and)
                      (NP (JJ:[1148..1156] valproic) (NN:[1157..1161] acid))))))))))
      (,:[1161..1162] ,) (CC:[1163..1166] and)
      (VP (MD:[1167..1170] can)
        (VP (VB:[1171..1173] be)
          (VP (VBN:[1175..1184] inhibited)
            (NP-1 (-NONE-:[1184..1184] *))
            (ADVP (RB:[1185..1197] considerably))
            (PP (IN:[1198..1200] by)
              (NP-LGS (NN:[1201..1209] SKF-525A) (CC:[1210..1213] and)
                      (NN:[1214..1224] metyrapone)))))))
    (.:[1224..1225] .)))

;sentence 8 Span:1226..1383
;alpha-Naphthoflavone (ANF) is  also an inhibitor for the reaction catalyzed
;in BNF-treated rats, but stimulated  the microsomal activity in DEX-treated
;rats.
;[1226..1246]:substance:"alpha-Naphthoflavone"
;[1248..1251]:substance:"ANF"
;[1265..1274]:substance:"inhibitor"
;[1305..1308]:substance:"BNF"
;[1366..1369]:substance:"DEX"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1226..1246] alpha-Naphthoflavone))
      (NP (-LRB-:[1247..1248] -LRB-) (NN:[1248..1251] ANF)
          (-RRB-:[1251..1252] -RRB-)))
    (VP
      (VP (VBZ:[1253..1255] is)
        (ADVP (RB:[1257..1261] also))
        (NP-PRD
          (NP (DT:[1262..1264] an) (NN:[1265..1274] inhibitor))
          (PP (IN:[1275..1278] for)
            (NP
              (NP (DT:[1279..1282] the) (NN:[1283..1291] reaction))
              (VP (VBN:[1292..1301] catalyzed)
                (NP (-NONE-:[1301..1301] *))
                (PP-LOC (IN:[1302..1304] in)
                  (NP
                    (ADJP (NN:[1305..1308] BNF) (HYPH:[1308..1309] -)
                          (VBN:[1309..1316] treated))
                    (NNS:[1317..1321] rats))))))))
      (,:[1321..1322] ,) (CC:[1323..1326] but)
      (VP (VBD:[1327..1337] stimulated)
        (NP (DT:[1339..1342] the) (JJ:[1343..1353] microsomal)
            (NN:[1354..1362] activity))
        (PP-LOC (IN:[1363..1365] in)
          (NP
            (ADJP (NN:[1366..1369] DEX) (HYPH:[1369..1370] -)
                  (VBN:[1370..1377] treated))
            (NNS:[1378..1382] rats)))))
    (.:[1382..1383] .)))

;sentence 9 Span:1384..1704
;Evidence has also been obtained  that specific antibodies raised against
;P450IIB1, P450IA1 or IA2, P450IIE1, and  P450IIIA2 inhibited the activation
;in liver microsomes from rats pretreated with  PB, BNF, INH and DEX
;respectively, suggesting the possible roles of several P450  enzymes in the
;bioactivation of 3-MeO-AAB.
;[1431..1441]:substance:"antibodies"
;[1457..1465]:cyp450:"P450IIB1"
;[1467..1474]:cyp450:"P450IA1"
;[1467..1471]...[1478..1481]:cyp450:"P450"..."IA2"
;[1483..1491]:cyp450:"P450IIE1"
;[1498..1507]:cyp450:"P450IIIA2"
;[1580..1582]:substance:"PB"
;[1584..1587]:substance:"BNF"
;[1589..1592]:substance:"INH"
;[1597..1600]:substance:"DEX"
;[1656..1669]:cyp450:"P450  enzymes"
;[1694..1703]:substance:"3-MeO-AAB"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[1384..1392] Evidence))
      (SBAR-3 (-NONE-:[1392..1392] *ICH*)))
    (VP (VBZ:[1393..1396] has)
      (ADVP (RB:[1397..1401] also))
      (VP (VBN:[1402..1406] been)
        (VP (VBN:[1407..1415] obtained)
          (NP (-NONE-:[1415..1415] *))
          (SBAR-3 (IN:[1417..1421] that)
            (S
              (NP-SBJ
                (NP (JJ:[1422..1430] specific) (NNS:[1431..1441] antibodies))
                (VP (VBN:[1442..1448] raised)
                  (NP (-NONE-:[1448..1448] *))
                  (PP (IN:[1449..1456] against)
                    (NP
                      (NP (NN:[1457..1465] P450IIB1))
                      (,:[1465..1466] ,)
                      (NP
                        (NP
                          (NML-1 (NN:[1467..1471] P450))
                          (NN:[1471..1474] IA1))
                        (CC:[1475..1477] or)
                        (NP
                          (NML-1 (-NONE-:[1477..1477] *P*))
                          (NN:[1478..1481] IA2)))
                      (,:[1481..1482] ,)
                      (NP (NN:[1483..1491] P450IIE1))
                      (,:[1491..1492] ,) (CC:[1493..1496] and)
                      (NP (NN:[1498..1507] P450IIIA2))))))
              (VP (VBD:[1508..1517] inhibited)
                (NP (DT:[1518..1521] the) (NN:[1522..1532] activation))
                (PP-LOC (IN:[1533..1535] in)
                  (NP (NN:[1536..1541] liver) (NNS:[1542..1552] microsomes)))
                (PP (IN:[1553..1557] from)
                  (NP
                    (NP (NNS:[1558..1562] rats))
                    (VP (VBN:[1563..1573] pretreated)
                      (NP (-NONE-:[1573..1573] *))
                      (PP (IN:[1574..1578] with)
                        (NP
                          (NP (NN:[1580..1582] PB) (,:[1582..1583] ,)
                              (NN:[1584..1587] BNF) (,:[1587..1588] ,)
                              (NN:[1589..1592] INH) (CC:[1593..1596] and)
                              (NN:[1597..1600] DEX))
                          (ADVP (RB:[1601..1613] respectively)))))))
                (,:[1613..1614] ,)
                (S-ADV
                  (NP-SBJ (-NONE-:[1614..1614] *))
                  (VP (VBG:[1615..1625] suggesting)
                    (NP
                      (NP (IN:[1626..1629] the) (JJ:[1630..1638] possible)
                          (NNS:[1639..1644] roles))
                      (PP (IN:[1645..1647] of)
                        (NP (JJ:[1648..1655] several)
                           (NN:[1656..1660] P450) (NNS:[1662..1669] enzymes))))
                    (PP (IN:[1670..1672] in)
                      (NP
                        (NP (DT:[1673..1676] the)
                            (NN:[1677..1690] bioactivation))
                        (PP (IN:[1691..1693] of)
                          (NP (NN:[1694..1703] 3-MeO-AAB)))))))))))))
    (.:[1703..1704] .)))

;sentence 10 Span:1705..1846
;The results obtained with  reconstituted monooxygenase systems containing
;various rat P450 enzymes are  highly supportive of this conclusion.
;[1746..1759]:substance:"monooxygenase"
;[1791..1803]:cyp450:"P450 enzymes"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1705..1708] The) (NNS:[1709..1716] results))
      (VP (VBN:[1717..1725] obtained)
        (NP (-NONE-:[1725..1725] *))
        (PP (IN:[1726..1730] with)
          (NP
            (NP (VBN:[1732..1745] reconstituted) (NN:[1746..1759] monooxygenase)
                (NNS:[1760..1767] systems))
            (VP (VBG:[1768..1778] containing)
              (NP (JJ:[1779..1786] various) (NN:[1787..1790] rat)
                 (NN:[1791..1795] P450) (NNS:[1796..1803] enzymes)))))))
    (VP (VBP:[1804..1807] are)
      (ADJP-PRD (RB:[1809..1815] highly) (JJ:[1816..1826] supportive)
        (PP (IN:[1827..1829] of)
          (NP (DT:[1830..1834] this) (NN:[1835..1845] conclusion)))))
    (.:[1845..1846] .)))

;sentence 11 Span:1847..2003
;Human liver microsomal activation of  3-MeO-AAB was also inhibited to various
;extents by antibodies raised against  P450IA2, P450MP, P450IIE1 and
;P450IIIA4.
;[1885..1894]:substance:"3-MeO-AAB"
;[1936..1946]:substance:"antibodies"
;[1963..1970]:cyp450:"P450IA2"
;[1972..1978]:cyp450:"P450MP"
;[1980..1988]:cyp450:"P450IIE1"
;[1993..2002]:cyp450:"P450IIIA4"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[1847..1852] Human) (NN:[1853..1858] liver)
          (JJ:[1859..1869] microsomal) (NN:[1870..1880] activation))
      (PP (IN:[1881..1883] of)
        (NP (NN:[1885..1894] 3-MeO-AAB))))
    (VP (VBD:[1895..1898] was)
      (ADVP (RB:[1899..1903] also))
      (VP (VBN:[1904..1913] inhibited)
        (NP-1 (-NONE-:[1913..1913] *))
        (PP (TO:[1914..1916] to)
          (NP (JJ:[1917..1924] various) (NNS:[1925..1932] extents)))
        (PP (IN:[1933..1935] by)
          (NP-LGS
            (NP (NNS:[1936..1946] antibodies))
            (VP (VBN:[1947..1953] raised)
              (NP (-NONE-:[1953..1953] *))
              (PP (IN:[1954..1961] against)
                (NP (NN:[1963..1970] P450IA2) (,:[1970..1971] ,)
                    (NN:[1972..1978] P450MP) (,:[1978..1979] ,)
                    (NN:[1980..1988] P450IIE1) (CC:[1989..1992] and)
                    (NN:[1993..2002] P450IIIA4))))))))
    (.:[2002..2003] .)))

;sentence 12 Span:2004..2159
;In a reconstituted system containing  purified forms of human P450, P450IA2
;was the most active in catalyzing  3-MeO-AAB, followed by P450IIIA4 and
;P450MP.
;[2066..2070]:cyp450:"P450"
;[2072..2079]:cyp450:"P450IA2"
;[2115..2124]:substance:"3-MeO-AAB"
;[2138..2147]:cyp450:"P450IIIA4"
;[2152..2158]:cyp450:"P450MP"
(SENT
  (S
    (PP (IN:[2004..2006] In)
      (NP
        (NP (DT:[2007..2008] a) (VBN:[2009..2022] reconstituted)
            (NN:[2023..2029] system))
        (VP (VBG:[2030..2040] containing)
          (NP
            (NP (VBN:[2042..2050] purified) (NNS:[2051..2056] forms))
            (PP (IN:[2057..2059] of)
              (NP (JJ:[2060..2065] human) (NN:[2066..2070] P450)))))))
    (,:[2070..2071] ,)
    (NP-SBJ (NN:[2072..2079] P450IA2))
    (VP (VBD:[2080..2083] was)
      (NP-PRD
        (NP (DT:[2084..2087] the) (RBS:[2088..2092] most)
            (JJ:[2093..2099] active))
        (PP (IN:[2100..2102] in)
          (S-NOM
            (NP-SBJ (-NONE-:[2102..2102] *))
            (VP (VBG:[2103..2113] catalyzing)
              (NP (NN:[2115..2124] 3-MeO-AAB))))))
      (,:[2124..2125] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[2125..2125] *))
        (VP (VBN:[2126..2134] followed)
          (NP (-NONE-:[2134..2134] *))
          (PP (IN:[2135..2137] by)
            (NP-LGS (NN:[2138..2147] P450IIIA4) (CC:[2148..2151] and)
                    (NN:[2152..2158] P450MP))))))
    (.:[2158..2159] .)))

;sentence 13 Span:2160..2350
;ANF, a known activator of  P450IIIA-catalyzed reactions, caused an increase
;in activation of 3-MeO-AAB in  human liver microsomal and P450IIIA4- and
;P450MP-containing reconstituted  systems.
;[2160..2163]:substance:"ANF"
;[2173..2182]:substance:"activator"
;[2187..2195]:cyp450:"P450IIIA"
;[2253..2262]:substance:"3-MeO-AAB"
;[2294..2303]:cyp450:"P450IIIA4"
;[2309..2315]:cyp450:"P450MP"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[2160..2163] ANF))
      (,:[2163..2164] ,)
      (NP
        (NP (DT:[2165..2166] a) (VBN:[2167..2172] known)
            (NN:[2173..2182] activator))
        (PP (IN:[2183..2185] of)
          (NP
            (NML (NN:[2187..2195] P450IIIA) (HYPH:[2195..2196] -)
                 (VBN:[2196..2205] catalyzed))
            (NNS:[2206..2215] reactions)))))
    (,:[2215..2216] ,)
    (VP (VBD:[2217..2223] caused)
      (NP
        (NP (DT:[2224..2226] an) (NN:[2227..2235] increase))
        (PP (IN:[2236..2238] in)
          (NP
            (NP (NN:[2239..2249] activation))
            (PP (IN:[2250..2252] of)
              (NP (NN:[2253..2262] 3-MeO-AAB)))))
        (PP (IN:[2263..2265] in)
          (NP
            (NP (JJ:[2267..2272] human) (NN:[2273..2278] liver)
                (JJ:[2279..2289] microsomal)
              (NML-1 (-NONE-:[2289..2289] *P*)))
            (CC:[2290..2293] and)
            (NP
              (NML (NN:[2294..2303] P450IIIA4) (HYPH:[2303..2304] -)
                (NML-2 (-NONE-:[2304..2304] *P*)))
              (NML-3 (-NONE-:[2304..2304] *P*))
              (NML-1 (-NONE-:[2304..2304] *P*)))
            (CC:[2305..2308] and)
            (NP
              (NML (NN:[2309..2315] P450MP) (HYPH:[2315..2316] -)
                (NML-2 (VBG:[2316..2326] containing)))
              (NML-3 (VBN:[2327..2340] reconstituted))
              (NML-1 (NNS:[2342..2349] systems)))))))
    (.:[2349..2350] .)))

;sentence 14 Span:2351..2559
;From these results it is concluded that multiple P450 enzymes in rat  and
;human liver microsomes are involved in the bioactivation of 3-MeO-AAB, 
;regardless of its selective induction of the rat P450IA2 gene.
;[2400..2412]:cyp450:"P450 enzymes"
;[2485..2494]:substance:"3-MeO-AAB"
(SENT
  (S
    (PP (IN:[2351..2355] From)
      (NP (DT:[2356..2361] these) (NNS:[2362..2369] results)))
    (NP-SBJ-4
      (NP (PRP:[2370..2372] it))
      (SBAR-3 (-NONE-:[2372..2372] *EXP*)))
    (VP (VBZ:[2373..2375] is)
      (VP (VBN:[2376..2385] concluded)
        (NP-4 (-NONE-:[2385..2385] *))
        (SBAR-3 (IN:[2386..2390] that)
          (S
            (NP-SBJ-2
              (NP (JJ:[2391..2399] multiple)
                 (NN:[2400..2404] P450) (NNS:[2405..2412] enzymes))
              (PP-LOC (IN:[2413..2415] in)
                (NP
                  (NP (NN:[2416..2419] rat)
                    (NML-1 (-NONE-:[2419..2419] *P*)))
                  (CC:[2421..2424] and)
                  (NP (JJ:[2425..2430] human)
                    (NML-1 (NN:[2431..2436] liver) (NNS:[2437..2447] microsomes))))))
            (VP (VBP:[2448..2451] are)
              (VP (VBN:[2452..2460] involved)
                (NP-2 (-NONE-:[2460..2460] *))
                (PP-CLR (IN:[2461..2463] in)
                  (NP
                    (NP (DT:[2464..2467] the) (NN:[2468..2481] bioactivation))
                    (PP (IN:[2482..2484] of)
                      (NP (NN:[2485..2494] 3-MeO-AAB))))))
              (,:[2494..2495] ,)
              (ADVP (RB:[2497..2507] regardless)
                (PP (IN:[2508..2510] of)
                  (NP
                    (NP (PRP$:[2511..2514] its) (JJ:[2515..2524] selective)
                        (NN:[2525..2534] induction))
                    (PP (IN:[2535..2537] of)
                      (NP (DT:[2538..2541] the) (NN:[2542..2545] rat)
                          (NN:[2546..2553] P450IA2) (NN:[2554..2558] gene)))))))))))
    (.:[2558..2559] .)))

;section 15 Span:2563..2607
;PMID: 1988174 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2563..2567] PMID) (::[2567..2568] :) (CD:[2569..2576] 1988174)
        (NN:[2577..2578] -LSB-) (NNP:[2578..2584] PubMed) (::[2585..2586] -)
        (NN:[2587..2594] indexed) (IN:[2595..2598] for)
        (NNP:[2599..2607] MEDLINE-RSB-)))
